Results 81 to 90 of about 186,446 (142)

Drug Resistance Analysis of Pancreatic Cancer Based on Universally Differentially Expressed Genes. [PDF]

Int J Mol Sci
Xia J, Zheng L, Zhang H, Fan Q, Liu H, Wang O, Yan H.   +6 more
europepmc   +1 more source

Characterization of amyloid deposits in exocrine pancreatic tumors in cats. [PDF]

J Vet Diagn Invest
Sedghi Masoud N, Iwaide S, Itoh Y, Hisada M, Harada T, Machida N, Murakami T.   +6 more
europepmc   +1 more source

MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine‐needle aspiration

Cancer, 2003
D. Chhieng, E. Benson, I. Eltoum, M. Eloubeidi, N. Jhala, D. Jhala, G. Siegal, W. Grizzle, U. Manne   +8 more
semanticscholar   +1 more source

Clinicopathological and molecular characterization of KRAS wild-type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes. [PDF]

J Pathol
Toriyama K, Masago K, Shibata N, Haneda M, Kuwahara T, Natsume S, Kobayashi S, Fujita Y, Sasaki E, Yamao K, Kawashima H, Shimizu Y, Hara K, Yatabe Y, Hosoda W.   +14 more
europepmc   +1 more source

Is programmed death-ligand 1 positivity a predictor of poor survival in patients with different histological subtypes of pancreatic cancer?

Cytojournal
Canbey C, Şen S, Karabulut S, Özcan TB, Paşaoğlu E, Altun E, Kuzan TY, Ezberci F.   +7 more
europepmc   +1 more source

Attenuated immune surveillance during squamous cell transformation of pancreatic adenosquamous cancer defines new therapeutic opportunity for cancer interception. [PDF]

J Immunother Cancer
Chen X, Sun S, Li S, Yu S, Chen J, Chen X.   +5 more
europepmc   +1 more source

Comprehensive analysis of SQOR involvement in ferroptosis resistance of pancreatic ductal adenocarcinoma in hypoxic environments. [PDF]

Front Immunol
Lin Q, Guan S, Peng M, Zhang K, Zhang H, Mo T, Yu H.   +6 more
europepmc   +1 more source

Tumor Stroma Interactions Induce Chemoresistance in Pancreatic Ductal Carcinoma Cells Involving Increased Secretion and Paracrine Effects of Nitric Oxide and Interleukin-1β

Cancer Research, 2004
S. Müerköster, K. Wegehenkel, A. Arlt, M. Witt, B. Sipos, M. Kruse, T. Sebens, G. Klöppel, H. Kalthoff, U. Fölsch, H. Schäfer   +10 more
semanticscholar   +1 more source

Case report: a case of R0 resection in a patient with PD-L1-negative, microsatellite-stabilized advanced pancreatic cancer after down-stage treatment with a PD-1 inhibitor in combination with chemotherapy. [PDF]

J Cancer Res Clin Oncol
Dang J, Wang Q, Yang Y, Shang L, Kang Z, Jiang Y, Ren Y, Xiang H.   +7 more
europepmc   +1 more source

Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicenter prospective trial - trial protocol. [PDF]

BMC Surg
Abreu de Carvalho LF, Gryspeerdt F, Ceelen W, Geboes K, Ribeiro S, Hoorens A, Vandenbussche N, Claes KBM, Lecluyse C, Anisau A, Van Ongeval J, Lybaert W, Triest L, Vervaecke A, Sas S, Claerhout B, Beyls C, Sie M, Berrevoet F.   +18 more
europepmc   +1 more source